Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Aim(s): Assess the prognostic/predictive value of FOXM1 expression in pancreatic and pulmonary NECs and evaluate in vitro the potential antitumoral effect of Thiostrepton (TS), a FOXM1 inhibitor.
Materials and methods: FOXM1 expression (immunohistochemistry) was determined in a comprehensive retrospective cohort of pancreatic and pulmonary NECs treated by etoposide/carboplatin (EC). TS antiproliferative effect alone or with EC was assessed in vitro in BON-1/QGP-1 (pancreas) and H-227 (lung) cell lines and its mechanisms of action studied by RNAseq and dynamic DNA repair tests.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
To read the full abstract, please log into your ENETS Member account.